Pfizer Wins Further Drug Approval, Wells Fargo Buys U.K. Real Estate Assets, and 3 More Hot Stocks

Pfizer Inc. (NYSE:PFE): Pfizer’s Tofacitinib treatment for rheumatoid arthritis has won approval in Switzerland, joining Argentina, Kuwait, the United Arab Emirates, the U.S., Japan, and Russia to grant the drug approval. The drug can be used in patients who did not respond as well to other treatments. Tofacitinib is expected to be rolled out domestically this month, in conjunction with Takeda.